0
Obstructive Lung Diseases |

QVA149 Demonstrates Superior Improvements in Health Status, as Measured by SGRQ Total Score in Patients With Moderate-to-Severe COPD: Pooled Analysis From the FLIGHT1 and FLIGHT2 Studies

Paul Jones; Angel FowlerTaylor; Donald Banerji; Michael Larbig; Samopriyo Maitra
Author and Funding Information

St George's, University of London, London, United Kingdom; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Healthcare Pvt Ltd, Hyderabad, India


Chest. 2015;148(4_MeetingAbstracts):728A. doi:10.1378/chest.2276477
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Posters V

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: The St. George's Respiratory Questionnaire (SGRQ) is an extensively used self-administered questionnaire that measures and quantifies health-related quality of life in patients with COPD. QVA149 (IND/GLY, a fixed-dose combination of indacaterol 110 μg [IND, a long-acting β2-agonist] and glycopyrronium 50 μg [GLY, a long-acting muscarinic antagonist]) is approved in over 50 countries including the EU, Japan, Canada, Mexico, Australia and Switzerland, for the maintenance treatment of COPD. The FLIGHT1 and FLIGHT2 studies evaluated the improvement in health status with twice-daily IND/GLY 27.5/12.5 μg compared with placebo and its monocomponents, as a key secondary objective in patients with moderate-to-severe COPD. We present the health status improvement with IND/GLY as measured by reduction in SGRQ total score, from the pooled data of the FLIGHT1 and FLIGHT2 studies.

METHODS: FLIGHT1 and FLIGHT2 were replicate, 12-week, multicenter, double-blind studies, which randomized patients with moderate-to-severe COPD (1:1:1:1) to IND/GLY 27.5/12.5 μg, IND 27.5 μg, GLY 12.5 μg or placebo (all delivered twice daily). Data from these studies were pooled to demonstrate the superiority of IND/GLY versus placebo for change in health status, and to access the percentage of patients achieving minimal clinically important difference (MCID ≥4 units) in SGRQ score at Week 12.

RESULTS: A total of 1891 patient’s data from the FLIGHT1 and FLIGHT2 studies were pooled and analyzed (IND/GLY, n=484; IND, n=478; GLY, n=480 and placebo, n=449). At Week 12, improvement in SGRQ total score exceeded the MCID with IND/GLY versus placebo (least squares mean treatment difference [LSMTD]: -5.0, p<0.001), while statistically significant improvements in SGRQ total score were observed versus IND (LSMTD: -1.7; p<0.05) and GLY (LSMTD: -1.5; p<0.05). The proportion of patients achieving the MCID of -4 units was significantly higher with IND/GLY (58.3%) compared with placebo (36.7%, odds ratio [OR] 2.50, p<0.001) and its monocomponents (IND [52.3%, OR 1.32, p<0.05] and GLY [48.8%, OR 1.50, p<0.01]).

CONCLUSIONS: In patients with moderate-to-severe COPD, IND/GLY demonstrated statistically significant improvement in health status compared with placebo and its monocomponents.

CLINICAL IMPLICATIONS: IND/GLY could be considered as an alternate therapeutic option for treatment of patients with moderate-to-severe COPD.

DISCLOSURE: Paul Jones: Consultant fee, speaker bureau, advisory committee, etc.: Received lecture and consultant fees from Novartis Angel FowlerTaylor: Employee: Employee of the study sponsor, Novartis and no other conflicts Michael Larbig: Employee: Employee of the study sponsor, Novartis and no other conflicts Samopriyo Maitra: Employee: Employee of the study sponsor, Novartis and no other conflicts Donald Banerji: Employee: Employee of the study sponsor, Novartis and no other conflicts

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543